|1.||Brombacher, Frank: 27 articles (01/2015 - 10/2002)|
|2.||Puri, Raj K: 25 articles (11/2015 - 01/2002)|
|3.||Finkelman, Fred D: 24 articles (12/2014 - 10/2002)|
|4.||Urban, Joseph F: 16 articles (09/2014 - 10/2002)|
|5.||Kawakami, Koji: 13 articles (01/2014 - 01/2002)|
|6.||Keegan, Achsah D: 13 articles (01/2013 - 04/2004)|
|7.||McKenzie, Andrew N J: 13 articles (07/2012 - 07/2002)|
|8.||Rothenberg, Marc E: 13 articles (05/2012 - 06/2003)|
|9.||Tsai, Fuu-Jen: 13 articles (09/2008 - 01/2002)|
|10.||Wang, Wei: 12 articles (10/2015 - 02/2002)|
01/01/2003 - "Regarding cellular immunity, high levels of IFN-gamma and no IL-4 were detected in primed mouse splenocytes and partial protection against infection was reached in animals vaccinated with the Brucella library compared to the control group."
05/01/1991 - "IL-4, however, did not significantly enhance the ability of IFN-gamma to induce macrophage clearance of the parasite, and IL-4 alone caused a slight increase in parasite infection in vitro. "
09/01/1992 - "In contrast, cells taken after clearance of a secondary infection produced IL-4 and acted as effective helper cells for anti-malarial antibody (Ab) synthesis in vitro, and thereby had the characteristics of Th2 cells. "
01/01/2015 - "IL-4 Protects the Mitochondria Against TNFα and IFNγ Induced Insult During Clearance of Infection with Citrobacter rodentium and Escherichia coli."
03/01/2008 - "Depletion of IL-4 cleared infection by 14 days post-challenge, and this clearance correlated with and was mediated by IFN-gamma. "
03/01/1997 - "Fluorescence-activated cell sorter analysis of day 14 TDLN exposed to IL-4 in vitro demonstrated a marked decrease in TCR zeta expression, comparable to that seen in late tumor-bearer TDLN. "
05/05/1989 - "In this way, we have identified a potent, non-cell autonomous, anti-tumor effect of IL-4 which is effective against a wide range of tumor cell types in vivo. "
01/01/2002 - "These data demonstrate that IL-4 (38-37)-PE38KDEL is effective in mediating significant antitumor effects in SCCHN and may represent an attractive therapeutic option for patients with advanced cancers of the upper aerodigestive tract."
05/01/2005 - "Compared with pR (encoding the extracellular region of M-CSFR(J6-1)), pF was more effective in inducing humoral and cytotoxic immune response, prolonging survival of mice challenged with SP2/0-CSFR(J6-1) tumor cells, and inducing IFN-gamma and IL-4 release by splenocytes. "
01/01/2007 - "The therapeutic efficacy of the DC vaccine was associated with increased tumor-specific IFN-g and IL-4 T-cell responses and cytolytic activity of splenic T cells. "
|3.||Asthma (Bronchial Asthma)
10/01/2012 - "In mouse models of allergic asthma, intervention with pTSX2 caused a significant reduction of sIgE and an increase of sIgG (P<0.05), significantly decreased the total cells and eosinophils in BALF (P<0.05), obviously lowered IL-4 but increased IFN-γ in BALF and spleen homogenate (P<0.05), and diminished inflammatory cell infiltration and percentage of eosinophils in the lung tissues. "
01/01/2012 - "IL-4 production induced by LPS was significantly greater (p < 0.05) in both asthma groups compared to atopic non-asthmatics and non-atopic healthy subjects. "
01/01/2001 - "We report the results of initial clinical trials, which demonstrate clinical efficacy of this naturally occurring IL-4 antagonist as a therapeutic agent in asthma."
01/01/2015 - "In the ADEM study, the minor alleles of ADAM33 rs511898 and rs528557 and the ORMDL3/GSDMB rs7216389 polymorphisms were negatively associated, whereas the minor alleles of IL4 rs2243250 and rs2070874 polymorphisms were positively associated with childhood asthma. "
02/01/2014 - "[Association study of bronchial asthma with polymorphisms of IL-4 and IL-4R receptor genes]."
05/01/2014 - "Neutralizing interleukin-4 antibody therapy given only in the newborn period ameliorates inflammation and restores vascularity and β-cell function into adulthood, demonstrating a novel role for Th2 immune responses in the induction and progression of T2D. "
05/15/2013 - "In particular, the presence of IFN-γ (Th1 inflammation) or the prolonged exposure to IL-4 (chronic Th2 inflammation) promotes apoptosis of monocytes/macrophages and causes resistance to M2c differentiation, thus provoking impaired clearance of apoptotic neutrophils, uncontrolled accumulation of apoptotic cells, and persistent inflammation. "
01/01/2012 - "Our studies provide new insight into the role of IL-4 during the early phases of pulmonary sensitization: The inhibitory activity of pulmonary epithelial cells in homeostasis is reversed in the presence of IL-4, which is secreted in the context of Th2-dominated allergic airway inflammation. "
09/01/2011 - "In summary, these studies suggest that Se supplementation of macrophages produces endogenous activators to mediate the PPARγ-dependent switch from M1 to M2 phenotype in the presence of IL-4, possibly affecting pathways of wound healing and inflammation resolution."
10/01/2010 - "Overall, results from this study add to the link between Th2-driven inflammation and neutrophilia in the equine model and further extend the characterization of IL-4 effects on neutrophils."
12/01/1999 - "To determine the efficacy of intra-articular IL-4 gene therapy in an animal model of arthritis using a retroviral vector, a retrovirus encoding rat IL-4 (DA-IL-4) was engineered, purified and concentrated to high titer (>/=109 CFU/ml). "
02/01/2002 - "These studies represent a unique opportunity to analyze the role of IL-4 and its absence on an autoimmune murine model of arthritis."
01/01/2015 - "IL-4 treatment decreased the incidence and severity of arthritis in a mouse AS model, and polarized macrophages from a classical M1 subtype to an M2 subtype in vivo and in vitro. "
01/01/2015 - "We injected IL-4 into the articular cavity and evaluated its effects on PGIA by incidence of arthritis, clinical and pathological arthritis severity and PET tracer uptake. "
08/19/2014 - "Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis."
|1.||Interleukin-10 (Interleukin 10)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|6.||Interleukin-5 (Interleukin 5)
|7.||Interferon-gamma (Interferon, gamma)
|8.||Immunoglobulin E (IgE)
|4.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)